Drugs that contain Lefamulin Acetate

1. List of Xenleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8153689 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Mar, 2028

(5 years from now)

US8071643 NABRIVA Pleuromutilin derivatives for the treatment of diseases mediated by microbes
Jan, 2029

(5 years from now)

US9120727 NABRIVA Process for the preparation of pleuromutilins
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 19, 2024
Generating Antibiotic Incentives Now (GAIN) Aug 19, 2029

NCE-1 date: August, 2028

Market Authorisation Date: 19 August, 2019

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic